EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) (clinicaltrials.gov) - Oct 6, 2026 - P2 | N=140 | Recruiting | Sponsor: Novartis Pharmaceuticals | N=104 ➔ 140 | Trial completion date: Sep 2030 ➔ Jun 2031 | Trial primary completion date: Aug 2028 ➔ Jan 2029
Enrollment change • Trial completion date • Trial primary completion date • Pediatrics • PIK3CA
|